BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1035 related articles for article (PubMed ID: 32051287)

  • 1. Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.
    Zhang M; Huang L; Ding G; Huang H; Cao G; Sun X; Lou N; Wei Q; Shen T; Xu X; Cao L; Yan Q
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32051287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.
    Highfill SL; Cui Y; Giles AJ; Smith JP; Zhang H; Morse E; Kaplan RN; Mackall CL
    Sci Transl Med; 2014 May; 6(237):237ra67. PubMed ID: 24848257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles.
    Wei Z; Zhang X; Yong T; Bie N; Zhan G; Li X; Liang Q; Li J; Yu J; Huang G; Yan Y; Zhang Z; Zhang B; Gan L; Huang B; Yang X
    Nat Commun; 2021 Jan; 12(1):440. PubMed ID: 33469052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-Associated Microglia/Macrophages as a Predictor for Survival in Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance Overcoming Strategy by Combination Therapy.
    Urbantat RM; Jelgersma C; Brandenburg S; Nieminen-Kelhä M; Kremenetskaia I; Zollfrank J; Mueller S; Rubarth K; Koch A; Vajkoczy P; Acker G
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
    Han MG; Jang BS; Kang MH; Na D; Kim IA
    Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon Gamma Inhibits CXCL8-Induced Proliferation and Migration of Pancreatic Cancer BxPC-3 Cell Line via a RhoGDI2/Rac1/NF-κB Signaling Pathway.
    Zhang M; Ding G; Zhou L; Shen T; Xu X; Zhao T; Jia S; Cao L
    J Interferon Cytokine Res; 2018 Sep; 38(9):413-422. PubMed ID: 30192158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCL8 Associated Dendritic Cell Activation Marker Expression and Recruitment as Indicators of Favorable Outcomes in Colorectal Cancer.
    Li E; Yang X; Du Y; Wang G; Chan DW; Wu D; Xu P; Ni P; Xu D; Hu Y
    Front Immunol; 2021; 12():667177. PubMed ID: 34025668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of tumor-associated macrophages in primary hepatocellular carcinoma and its related targeting therapy.
    Deng L; He K; Pan Y; Wang H; Luo Y; Xia Q
    Int J Med Sci; 2021; 18(10):2109-2116. PubMed ID: 33859517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy.
    Schoonderwoerd MJA; Koops MFM; Angela RA; Koolmoes B; Toitou M; Paauwe M; Barnhoorn MC; Liu Y; Sier CFM; Hardwick JCH; Nixon AB; Theuer CP; Fransen MF; Hawinkels LJAC
    Clin Cancer Res; 2020 Jul; 26(14):3831-3842. PubMed ID: 32332012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.
    Imai D; Yoshizumi T; Okano S; Itoh S; Ikegami T; Harada N; Aishima S; Oda Y; Maehara Y
    J Surg Res; 2019 Aug; 240():115-123. PubMed ID: 30927618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
    Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients.
    Hiraoka N; Ino Y; Hori S; Yamazaki-Itoh R; Naito C; Shimasaki M; Esaki M; Nara S; Kishi Y; Shimada K; Nakamura N; Torigoe T; Heike Y
    Cancer Sci; 2020 Aug; 111(8):3057-3070. PubMed ID: 32495519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.
    Torrens L; Montironi C; Puigvehí M; Mesropian A; Leslie J; Haber PK; Maeda M; Balaseviciute U; Willoughby CE; Abril-Fornaguera J; Piqué-Gili M; Torres-Martín M; Peix J; Geh D; Ramon-Gil E; Saberi B; Friedman SL; Mann DA; Sia D; Llovet JM
    Hepatology; 2021 Nov; 74(5):2652-2669. PubMed ID: 34157147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer.
    Ding G; Shen T; Yan C; Zhang M; Wu Z; Cao L
    BMC Cancer; 2019 Nov; 19(1):1053. PubMed ID: 31694582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of SMAD4 Promotes Colorectal Cancer Progression by Recruiting Tumor-Associated Neutrophils via the CXCL1/8-CXCR2 Axis.
    Ogawa R; Yamamoto T; Hirai H; Hanada K; Kiyasu Y; Nishikawa G; Mizuno R; Inamoto S; Itatani Y; Sakai Y; Kawada K
    Clin Cancer Res; 2019 May; 25(9):2887-2899. PubMed ID: 30705034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts.
    Bortolomeazzi M; Keddar MR; Montorsi L; Acha-Sagredo A; Benedetti L; Temelkovski D; Choi S; Petrov N; Todd K; Wai P; Kohl J; Denner T; Nye E; Goldstone R; Ward S; Wilson GA; Al Bakir M; Swanton C; John S; Miles J; Larijani B; Kunene V; Fontana E; Arkenau HT; Parker PJ; Rodriguez-Justo M; Shiu KK; Spencer J; Ciccarelli FD
    Gastroenterology; 2021 Oct; 161(4):1179-1193. PubMed ID: 34197832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.